Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Cooperation of Pharmacists and Nurses Is Necessary for XELOX Therapy
April 5, 2010
- Dr Kondo Reappointed PMDA Chief Executive
April 5, 2010
- Erbitux Approved for Use in First-Line Therapy
April 5, 2010
- NovoSeven Approved for Bleeding in Congenial FVII Deficiency Patients
April 5, 2010
- Shionogi to Break from Long-Listed Drugs
April 5, 2010
- Korosho to Lift 14-Day Limit on Prescriptions of Thalidomide
April 5, 2010
- Hisamitsu Launches Fentanyl Transdermal System in the US
April 5, 2010
- Korosho Explains New Premium to Semi-Public Hospital Groups
April 5, 2010
- Research Funds Should Be Provided Based on Contracts: Dr Imamura
April 5, 2010
- No Serious Concern about Domestic Flu Vaccines
March 29, 2010
- Pharmacists Should Provide More Personalized Medication Guidance: Mr Isobe
March 29, 2010
- In the Blink of an Eye
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
March 29, 2010
- Astellas to Continue to Directly Address OSI's Stockholders
March 29, 2010
- Takeda Withdraws MAA for Actos + Metformin Once-Daily Combination
March 29, 2010
- Sapporo City to Subsidize Hib Vaccines from FY2010
March 29, 2010
- Erbitux to Be Approved for Use in 1st-Line Therapy
March 29, 2010
- Chugai Applies for Combination of Herceptin, Xeloda for Gastric Cancer in Japan
March 29, 2010
- Only 12% of Free Coupons for Cervical Cancer Checkups Used
March 29, 2010
- Bayer to Enhance Links between Diagnostic Imaging, Oncology BU
March 29, 2010
- Actemra Applied for Additional Indication in the US
March 29, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…